TY - JOUR
T1 - Refractory overactive bladder in men
T2 - Update on novel therapies
AU - Ng, Casey K.
AU - Gonzalez, Ricardo R.
AU - Te, Alexis E.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2006/11
Y1 - 2006/11
N2 - Overactive bladder (OAB) in men is an entity that may be challenging to diagnose and treat, especially in the presence of bladder outlet obstruction. The application of oral medical treatments of lower urinary tract symptoms attributed to benign prostatic hyperplasia has traditionally utilized α-adrenergic blockers and 5α-reductase inhibitors. After failure of oral medical therapies, surgical options are traditionally offered. Even after surgical options are successful, lower urinary tract symptoms that are secondary to OAB persist. These patients merit a trial of antimuscarinic drugs. Additionally, certain patients with concomitant bladder outlet obstruction who have not been surgically relieved can still merit a trial of antimuscarinic drugs without significant risk of developing urinary retention. When these oral antimuscarinic drugs fail, options still remain for treating men with refractory OAB. Successful application of various diagnostic approaches and the initiation of conservative options as well as other options, such as neuromodulation for refractory urgency and urge incontinence, can help the patient. Finally, emerging data support the use of intradetrusor injections of botulinum toxin for refractory OAB.
AB - Overactive bladder (OAB) in men is an entity that may be challenging to diagnose and treat, especially in the presence of bladder outlet obstruction. The application of oral medical treatments of lower urinary tract symptoms attributed to benign prostatic hyperplasia has traditionally utilized α-adrenergic blockers and 5α-reductase inhibitors. After failure of oral medical therapies, surgical options are traditionally offered. Even after surgical options are successful, lower urinary tract symptoms that are secondary to OAB persist. These patients merit a trial of antimuscarinic drugs. Additionally, certain patients with concomitant bladder outlet obstruction who have not been surgically relieved can still merit a trial of antimuscarinic drugs without significant risk of developing urinary retention. When these oral antimuscarinic drugs fail, options still remain for treating men with refractory OAB. Successful application of various diagnostic approaches and the initiation of conservative options as well as other options, such as neuromodulation for refractory urgency and urge incontinence, can help the patient. Finally, emerging data support the use of intradetrusor injections of botulinum toxin for refractory OAB.
UR - http://www.scopus.com/inward/record.url?scp=33750518190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750518190&partnerID=8YFLogxK
U2 - 10.1007/s11934-006-0054-5
DO - 10.1007/s11934-006-0054-5
M3 - Article
C2 - 17052441
AN - SCOPUS:33750518190
VL - 7
SP - 456
EP - 461
JO - Current Urology Reports
JF - Current Urology Reports
SN - 1527-2737
IS - 6
ER -